Sprint Bioscience AB
Research Sprint Bioscience AB (SPRINT) on Bullrun: market cap SEK 372.47M, P/E 4.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPRINT
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 372.47M
- P/E4.1
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 12.89M
- Free cash flow-SEK 19.29M
Valuation Snapshot
latest market cap is SEK 372.47M; P/E is 4.1.
Peer valuation comparison
Latest P/E is 4.1x versus a Healthcare sector median of 24.64x (83.3% below).
Latest P/E is 4.1x versus a Sweden median of 18.18x (77.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 167.17M | SEK 91.74M | SEK 84.16M | 92.2% | 0.82 | SEK 126.70M | n/a | SEK 119.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | SEK 372.47M | 4.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sprint Bioscience AB's market cap?
Sprint Bioscience AB's market capitalization is SEK 372.47M.
What is Sprint Bioscience AB's P/E ratio?
Sprint Bioscience AB's price-to-earnings (P/E) ratio is 4.1.
What does Sprint Bioscience AB do?
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases.